Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 30 of 40 · 1919 articles
This label update details how injectable methylprednisolone can be used in acute/critical situations for inflammatory bowel diseases (regional enteritis/Crohn’s disease and ulcerative colitis), including dosing and...
RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.
Children with autoimmune gastrointestinal diseases can have impaired bone health.
Low-FODMAP diets are commonly used to reduce GI symptoms in IBS and sometimes in UC.
The study identifies a probiotic species (B. pseudolongum) and its acetate production as potential ways to limit a genotoxic E. coli and reduce inflammation in a mouse model — suggesting a microbiome-based avenue that...
If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived...
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...
A new Phase 2 study is testing an investigational injectable drug (called “627”) for moderate to severe ulcerative colitis. People with UC who have not responded to or cannot tolerate current therapies are the intended...
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Colectomy. The original article is from Journal of Gastroenterology and...
Vitamin D deficiency is common in people with IBD and may relate to disease activity, complications, and quality of life; understanding this link could influence monitoring and adjunctive care.
If findings translate to humans, creatine might help protect the gut lining and blood vessels during flare and remission, potentially supporting recovery of gut barrier function in ulcerative colitis.
The work links a missing bacterial metabolite (HDCA) to macrophage metabolism and reduced intestinal inflammation in experimental models, highlighting a potential microbiome-derived pathway that could be targeted for...
This study identifies plant extracts—especially Commiphora gileadensis—that reduced inflammation and tissue injury in cell assays and an acute rat model of ulcerative colitis, suggesting new leads for future IBD drug...
TRPV channels are proposed as integrative mediators of inflammation, angiogenesis, and oxidative stress in IBD, suggesting new mechanistic targets that could eventually yield novel therapies for Crohn's disease and...
Patients with IBD may see TREMFYA appearing more widely as a treatment option and influencing which drugs companies prioritize. Rising sales and trial signals can speed access but don’t replace clinical guidance about...
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Ulcerative colitis and Research and clinical trials. The original article is from Cochrane Database of Systematic...
Older adults with IBD may face different infection risks when treated with advanced biologic therapies. This study aims to compare hospitalizations for serious infections after starting vedolizumab (ENTYVIO) versus TNF...
People with UC on or starting vedolizumab may be interested because the study tests whether adding an oral CurQD supplement improves remission rates compared with vedolizumab alone. The trial could inform whether this...
Cure8 found this source from Journal of gastroenterology and hepatology, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials....
The study identifies a candidate compound (NCTD) that reduced inflammation and tissue damage in a rat ulcerative colitis model and implicates specific inflammatory, epigenetic, metabolic, and antioxidant pathways —...
The study identifies specific anti-inflammatory compounds in Artemisia scoparia and shows they reduce inflammation in cell and mouse models of ulcerative colitis, suggesting potential new leads for drug or...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
Vedolizumab blood levels can vary with disease activity; a model that links intestinal α4β7 expression to drug exposure helps explain why some patients have lower drug levels and may need different dosing. This could...
Higher, optimised doses of prolonged-release mesalazine were linked with fewer clinical recurrences over 12 months in adults with mild-to-moderate UC, which could influence treatment decisions about mesalazine dose and...
This preclinical study suggests quince gel reduced inflammation, oxidative stress, and tissue injury in a rat model of ulcerative colitis and identifies quercetin as a likely active component. Findings point to possible...
Metformin is a common, inexpensive drug with possible anti-inflammatory effects; this review compiles preclinical and early clinical data suggesting it might influence ulcerative colitis biology. Readers may want to know...
This preclinical study identifies benzoylpaeoniflorin (BPF) as a compound that improved experimental colitis in mice by changing macrophage polarization via the RNF31–DPEP2–NF-κB pathway. It highlights a possible...
Local fundraisers both raise money for IBD research/support and help build community and visibility for people living with Crohn’s disease and ulcerative colitis. Hearing personal stories can reduce isolation and point...
This NIH-funded project identifies probiotic metabolic pathways that protect gut barrier integrity in a diet-dependent way, which could explain mixed clinical trial results and point to biomarkers to select patients...
People with IBD and their clinicians often worry that anorectal surgery like hemorrhoidectomy could cause complications, flares, or loss of continence. This study suggests that, in a selected multicenter European cohort,...
If a serious infection occurs while on an anti‑TNF drug, patients and clinicians face difficult decisions about when and whether to restart biologic therapy. This case shows one example where switching to mirikizumab...
Automated, consistent scoring of the UCEIS could reduce subjectivity and variability in endoscopic assessment of ulcerative colitis, which matters for clinical trials, central reading, and potentially treatment decisions...
Early symptomatic improvement on filgotinib may predict longer-term gains in disease-specific quality-of-life for people with ulcerative colitis, which could help patients and clinicians set expectations during...
The study identifies a fungal β-glucan that reduced inflammation and altered the gut microbiome and short-chain fatty acids in a mouse model of ulcerative colitis, which could inform future nutritional or therapeutic...
Steroid dependency affects many people with ulcerative colitis and can change long-term treatment plans. This study explores clinical factors and uses an AI clustering method to visualize different risk patterns, which...
IBD can cause inflammation outside the gut; this report shows rare eye, facial muscle, and salivary gland involvement occurring at the time of ulcerative colitis diagnosis in a child, which could affect evaluation and...
Mesalazine is commonly used in UC; rare pulmonary toxicity can present with fever and progressive breathlessness. Early recognition and stopping the drug plus corticosteroids may lead to recovery and avoid invasive...
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....
Many people with UC try dietary changes to manage symptoms. This randomized pilot trial directly compared two popular diets and did not find a clear difference in symptom improvement, but high dropout limits confidence.
Many people with IBD still experience active disease, poor quality of life, work impairment, and depression even while on advanced therapies — highlighting gaps in how we measure and manage treatment success. Who this...
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
People with IBD often take biologics and may need or want implant-based breast surgery.
This mouse study identifies a novel peptide that reduced DSS-induced colitis and points to mast cells and fibroblast–mast cell interactions as potential therapeutic targets. It also showed additive benefit when combined...
